<DOC>
	<DOCNO>NCT00261833</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind , multicenter phase III/IV study compare efficacy safety Zemaira® placebo subject emphysema due alpha1-proteinase inhibitor deficiency . The effect Zemaira® progression emphysema assess decline lung density , measure compute tomography ( CT ) .</brief_summary>
	<brief_title>Zemaira Subjects With Emphysema Due Alpha1-Proteinase Inhibitor Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>18 65 year age willing sign inform consent . Males nonpregnant , nonlactating female whose screen pregnancy test negative use contraceptive method deem reliable investigator . Diagnosis alpha1proteinase inhibitor ( A1PI ) deficiency ( serum A1PI level &lt; 11 μM &lt; 80 mg/dL ) . This include newly diagnose subject , previously untreated subject , currently treat subject , subject currently treatment therapy treatment past . Subjects emphysema forced expiratory volume 1 second ( FEV1 ) ≥ 35 % ≤ 70 % ( predict ) . No sign chronic acute Hepatitis A , Hepatitis B , Hepatitis C HIV infection ( negative serology HIV viral hepatitis ) . In case positive serology viral hepatitis , vaccination status negative IgM available . Any relevant chronic disease history relevant disease ( e.g. , severe renal insufficiency ) except respiratory liver disease secondary alpha1proteinase inhibitor deficiency . Subjects wellcontrolled , chronic disease may include consultation treat physician sponsor . Current evidence alcohol abuse history abuse illegal and/or legally prescribe drug barbiturate , benzodiazepine , amphetamine , cocaine , opioids , cannabinoids . History allergy , anaphylactic reaction , severe systemic response human plasma derive product , know mannitol hypersensitivity , history prior adverse reaction mannitol . History transfusion reaction . Selective IgA deficiency . Acute illness within one week prior first administration investigational medicinal product ( IMP ) . Start treatment recovery possible . Current tobacco smoker ( smoke cease least 6 month prior study inclusion ) . Subjects positive cotinine test due nicotine replacement therapy ( e.g . patch , chew gum ) snuff eligible . Conditions behavior interfere attend schedule study visit opinion investigator . History noncompliance . Administration experimental new drug participation investigation market product within one month prior screen visit date . Inability perform necessary study procedure . Lung transplantation , lung volume reduction surgery lobectomy wait list surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Alpha1-proteinase inhibitor deficiency</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Chronic augmentation maintenance therapy</keyword>
</DOC>